Nektar Therapeutics Statistics

Total Valuation

Nektar Therapeutics has a market cap or net worth of GBP 137.49 million. The enterprise value is 102.62 million.

Market Cap	137.49M
Enterprise Value	102.62M

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+6.17%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	165.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	3.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.82
EV / Sales	1.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.77

Financial Position

The company has a current ratio of 4.24, with a Debt / Equity ratio of 4.22.

Current Ratio	4.24
Quick Ratio	3.65
Debt / Equity	4.22
Debt / EBITDA	n/a
Debt / FCF	-1.16
Interest Coverage	-5.47

Financial Efficiency

Return on equity (ROE) is -161.63% and return on invested capital (ROIC) is -25.77%.

Return on Equity (ROE)	-161.63%
Return on Assets (ROA)	-22.64%
Return on Capital (ROIC)	-25.77%
Revenue Per Employee	507,223
Profits Per Employee	-916,565
Employee Count	137
Asset Turnover	0.25
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +75.97% in the last 52 weeks. The beta is 0.61, so Nektar Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+75.97%
50-Day Moving Average	1.06
200-Day Moving Average	1.27
Relative Strength Index (RSI)	42.57
Average Volume (20 Days)	20,859

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.38

Income Statement

In the last 12 months, Nektar Therapeutics had revenue of GBP 69.49 million and -125.57 million in losses. Loss per share was -0.62.

Revenue	69.49M
Gross Profit	47.11M
Operating Income	-101.39M
Pretax Income	-125.58M
Net Income	-125.57M
EBITDA	-97.13M
EBIT	-101.39M
Loss Per Share	-0.62

Full Income Statement

Balance Sheet

The company has 182.42 million in cash and 153.76 million in debt, giving a net cash position of 32.04 million.

Cash & Cash Equivalents	182.42M
Total Debt	153.76M
Net Cash	32.04M
Net Cash Per Share	n/a
Equity (Book Value)	36.47M
Book Value Per Share	0.20
Working Capital	163.32M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -131.74 million and capital expenditures -929,641, giving a free cash flow of -132.67 million.

Operating Cash Flow	-131.74M
Capital Expenditures	-929,641
Free Cash Flow	-132.67M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 67.80%, with operating and profit margins of -145.91% and -180.70%.

Gross Margin	67.80%
Operating Margin	-145.91%
Pretax Margin	-180.71%
Profit Margin	-180.70%
EBITDA Margin	-139.78%
EBIT Margin	-145.91%
FCF Margin	n/a

Dividends & Yields

Nektar Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.17%
Shareholder Yield	-6.17%
Earnings Yield	-91.33%
FCF Yield	-96.49%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Nektar Therapeutics has an Altman Z-Score of -16.26. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-16.26
Piotroski F-Score	n/a